Some Biostatistical Considerations About Real-World Data and Evidence in Clinical Studies, Especially for Regulatory Purposes

References

• Belen, O., Concato, S., and Kraus, S. (2021), “FDA Approval Demonstrates the Role of Real-World Evidence in Regulatory Decision-Making on Drug Effectiveness,” available at https://www.fda.gov/drugs/news-events-human-drugs/fda-approval-demonstrates-role-real-world-evidence-regulatory-decision-making-drug-effectiveness.
   Google Scholar
• Campbell, G. (2011), “Bayesian Statistics in Medical Devices: Innovation Sparked by FDA,” Journal of Biopharmaceutical Statistics, 21, 871–887. DOI: 10.1080/10543406.2011.589638.
   PubMed Web of Science ®Google Scholar
• Campbell, G., and Yue, L.Q. (2016), “Statistical Innovations in the Medical Device World Sparked by the FDA,” Journal of Biopharmaceutical Statistics, 26, 3–16. DOI: 10.1080/10543406.2015.1092037.
   PubMed Web of Science ®Google Scholar
• Chen, J., Ho, M., Lee, K., Song, Y., Fang, Y., Goldstein, B. A., He, W., Irony, T., Jiang, Q., van der Laan, M., Lee, H., Lin, X., Meng, Z., Mishra-Kalyani, P., Rockhold, F., Wang, H., and White, R. (2021), “The Current Landscape in Biostatistics of Real-World Data and Evidence: Clinical Study Design and Analysis,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2021.1883474.
   Web of Science ®Google Scholar
• Chen, W. C., Wang, C., Li, H., Lu, N., Tiwari, R., Xu, Y., and Yue, L. Q. (2020), “Propensity Score-Integrated Composite Likelihood Approach for Augmenting the Control Arm of a Randomized Controlled Trial by Incorporating Real-World Data,” Journal of Biopharmaceutical Statistics, 30, 508–520. DOI: 10.1080/10543406.2020.1730877.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. (FDA), (2010), “Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials,” available at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071072.htm.
   Google Scholar
• Food and Drug Administration. (FDA) (2016), “Leveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices: Guidance for Industry and Food and Drug Administration Staff,” available at http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM444591.pdf.
   Google Scholar
• Food and Drug Administration. (FDA), (2017), “Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices,” available at https://www.fda.gov/media/99447/download.
   Google Scholar
• Food and Drug Administration. (FDA) (2018), “Framework for FDA’s Real-World Evidence Program,” available at https://www.fda.gov/media/120060/download.
   Google Scholar
• Food and Drug Administration. (FDA) (2019), “Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drugs and Biologics Guidance for Industry,” available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-documents-using-real-world-data-and-real-world-evidence-fda-drugs-and-biologics-guidance.
   Google Scholar
• Food and Drug Administration. (FDA) (2021), “Examples of Real-World Evidence (RWE) Used in Medical Device Regulatory Decisions,” available at http://www.fda.gov/media/146258/dowload.
   Google Scholar
• Frobert, O., Lagerqvist, B., Olivecrona, G. K., Omerovic, E., Gudnason, T., Maeng, M., et al. (2013), “Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction,” New England Journal of Medicine, 369, 1587–1597. DOI: 10.1056/NEJMoa1308789.
   PubMed Web of Science ®Google Scholar
• Ho, M., van der Laan, M., Lee, H., Chen, J., Lee, K., Fang, Y., He, W., Irony, T., Jiang, Q., Lin, X., Meng, Z., Mishra-Kalyani, P., Rockhold, F., Song, Y., Wang, H., and White, R. (2021), “The Current Landscape in Biostatistics of Real-World Data and Evidence: Causal Inference Frameworks for Study Design and Analysis,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2021.1883475.
   Web of Science ®Google Scholar
• Kaptchuk, T. J., Goldman, P., Stone, D. A., and Stason, W. B. (2000), “Do Medical Devices Have Enhanced Placebo Effects?” Journal of Clinical Epidemiology, 53, 786–792. DOI: 10.1016/S0895-4356(00)00206-7.
   PubMed Web of Science ®Google Scholar
• Kopp-Schneider, A., Calderazzo, S., and Wiesenfarth, M. (2020), “Power Gains by Using External Information in Clinical Trials are Typically Not Possible When Requiring Strict Type I Error Control,” Biometrical Journal, 62, 361–374. DOI: 10.1002/bimj.201800395.
   PubMed Web of Science ®Google Scholar
• Levenson, M., He, W., Chen, J., Fang, Y., Faries, D., Goldstein, B. A., Ho, M., Lee, K., Mishra-Kalyani, P., Rockhold, F., Wang, H., and Zink, R. C. (2021), “Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2021.1883473.
   Web of Science ®Google Scholar
• Li, H., Chen, W. C., Wang, C., Lu, N., Song, C., Tiwari, R., Xu, Y., and Yue, L. Q. (2021), “Augmenting Both Arms of a Randomized Controlled Trial Using External Data: An Application of the Propensity Score-Integrated Approaches,” Statistics in Biosciences, 19, 1–11. DOI: 10.1007/s12561-021-09315-5.
   Google Scholar
• Rao, S. V., Hess, C. N., Barham, B., Aberle, L. H., Anstrom, K. J., Patel, T. B., et al. (2014), “A Registry-Based Randomized Trial Comparing Radial and Femoral Approaches in Women Undergoing Percutaneous Coronary Intervention: The SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) Trial,” JACC: Cardiovascular Interventions, 7, 857–867.
   PubMed Web of Science ®Google Scholar
• Vander Weele, T. J., and Ding, P. (2017), “Sensitivity Analysis in Observational Research: Introducing the E-value,” Annals of Internal Medicine, 167, 268–274. DOI: 10.7326/M16-2607.
   PubMed Web of Science ®Google Scholar
• Wang, C., Li, H., Chen, W. C., Lu, N., Tiwari, R., Xu, Y., and Yue, L. Q. (2019), “Propensity Score-Integrated Power Prior Approach for Incorporating Real-World Evidence in Single-Arm Clinical Studies,” Journal of Biopharmaceutical Statistics, 29, 731–748. DOI: 10.1080/10543406.2019.1657133.
   PubMed Web of Science ®Google Scholar
• Wang, C., Lu, N., Chen, W. C., Li, H., Tiwari, R., Xu, Y., and Yue, L. Q. (2020), “Propensity Score-Integrated Composite Likelihood Approach for Incorporating Real-World Evidence in Single-Arm Clinical Studies,” Journal of Biopharmaceutical Statistics, 30, 495–507. DOI: 10.1080/10543406.2019.1684309.
   PubMed Web of Science ®Google Scholar
• Yue, L. Q. (2018), “Leveraging Real-World Evidence Derived From Patient Registries for Premarket Medical Device Regulatory Decision-Making,” Statistics in Biopharmaceutical Research, 10, 98–103. DOI: 10.1080/19466315.2017.1422436.
   Web of Science ®Google Scholar
• Yue, L. Q., Lu, N., and Xu, Y. (2014), “Designing Premarket Observational Comparative Studies Using Existing Data as Controls: Challenges and Opportunities,” Journal of Biopharmaceutical Statistics, 24, 994–1010. DOI: 10.1080/10543406.2014.926367.
   PubMed Web of Science ®Google Scholar